Research
January 26, 2022
UAMS’ Kevin D. Raney, Ph.D., Named Fellow of American Association for the Advancement of Science
LITTLE ROCK — Kevin D. Raney, Ph.D., a research leader at the University of Arkansas for Medical Sciences (UAMS), has been elected a Fellow of the American Association for the Advancement of Science (AAAS), the world’s largest general scientific society and publisher of the Science family of journals. Raney is professor and chair of the…
January 25, 2022
UAMS Research Team Finds COVID-19 Has Mutation Limits
LITTLE ROCK — A University of Arkansas for Medical Sciences (UAMS) research team has found that while the coronavirus can create dangerous variants like delta and omicron, its ability to mutate has limits that should help drug and vaccine makers trying to thwart it. Drawing from global databases with millions of sequenced SARS-CoV-2 genomes, the…
December 27, 2021
UAMS Stays on Course despite New Challenges from COVID-19 Pandemic
As UAMS did everything it could to fight COVID-19, it maintained its commitment to excellence and its core values during the public health crisis — a commitment that was noticed by multiple national organizations and publications.
December 7, 2021
UAMS Researchers Discover Potential Way to Control Immune Responses
LITTLE ROCK — Researchers at the University of Arkansas for Medical Sciences (UAMS) have discovered how a key switch in the body’s immune response is turned on and off, opening the door to new treatments for those with life-threatening, uncontrolled immune responses.
November 26, 2021
UAMS Testing ‘Big Advance’ in Spinal Cord Stimulation; First Arkansas Participant Now Pain Free
Cornelia Ann Smith’s severe chronic back pain disappeared almost as soon as the experimental spinal cord stimulator was activated in a procedure at the University of Arkansas for Medical Sciences (UAMS). “I realized the device was helping me immediately,” the Calico Rock, Ark., resident said. Then, back home, it really began to sink in. “I…
November 23, 2021
UAMS’ Analiz Rodriguez, M.D., Ph.D., Selected for Diversity in Clinical Trials Career Development Program
LITTLE ROCK — The Bristol Myers Squibb Foundation (BMSF), along with its partners National Medical Fellowships and the American Association for Cancer Research, selected University of Arkansas for Medical Sciences (UAMS) neurosurgeon Analiz Rodriguez, M.D., Ph.D., to participate in its Diversity in Clinical Trials Career Development Program.
November 22, 2021
UAMS Researchers Receive $1.5 Million to Study Impact of Maternal Diabetes on Fetal Neurodevelopment
LITTLE ROCK —Researchers at the University of Arkansas for Medical Sciences (UAMS) hope to gain important insights about fetal neurodevelopment in a new study with diabetic pregnant mothers. Funded by a four-year, $1.5 million grant from the National Institutes of Health (NIH), the first study of its kind will use advanced fetal monitoring techniques and…
November 15, 2021
UAMS Receives $18.9 Million NIH Award to Address Health Disparities
LITTLE ROCK — The University of Arkansas for Medical Sciences (UAMS) has received $18.9 million from the National Institutes of Health (NIH) to support new research and interventions that will focus on reducing cancer and cardiovascular disease disparities among people who live in rural areas and African American populations across Arkansas. The five-year award from…
November 4, 2021
UAMS Receives Full Accreditation, Area of Distinction for its Human Research Protection Program
The University of Arkansas for Medical Sciences (UAMS) Human Research Protection Program was fully accredited recently for another five years by the Association for the Accreditation of Human Research Protection Programs (AAHRPP). UAMS became one of the first 25 institutions in the United States to receive the accreditation in 2005 and has maintained it since…
November 1, 2021
NIH Awards $13.8 Million to Test UAMS-Discovered Drug for Methamphetamine Use Disorder Treatment
A drug discovered at the University of Arkansas for Medical Sciences (UAMS) to counter the effects of methamphetamine will be tested in a phase 2 clinical trial as the only potential treatment of its kind for methamphetamine use disorder.
Previous page Next page